Digest Réseau Comment ça marche
Réseau
/
Sociétés
Al
Non vérifié

Alzheon, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéScience

17 communiqués de presse

Voir tous les communiqués de presse
06/07/2026
Événements
Expos
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
14/04/2026
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
07/04/2026
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Psychiatrie
Médecine - Divers
Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
03/02/2026
Science
Biotechnologie
Industrie pharmaceutique
Santé
Médecine - Divers
Industrie
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
02/12/2025
Science
Finance
Médecine - Divers
Associations/Professionnels
Biotechnologie
Santé Publique
Industrie pharmaceutique
Santé
Industrie
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
19/11/2025
Événements
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
14/10/2025
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Industrie
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
15/07/2025
Santé
Santé Publique
Industrie pharmaceutique
Biotechnologie
Web et Réseaux Sociaux
Événements
Industrie
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
10/04/2025
Événements
Industrie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0
18/03/2025
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé
Hygiène alimentaire
Médecine - Divers
Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025
Source
Alzheon, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0